Aimmune Therapeutics Inc (NASDAQ:AIMT) saw unusually large options trading on Thursday. Traders acquired 2,787 call options on the stock. This represents an increase of approximately 1,653% compared to the average daily volume of 159 call options.
Shares of AIMT traded up $0.98 during trading hours on Friday, reaching $26.06. 636,036 shares of the company’s stock traded hands, compared to its average volume of 645,766. The company has a market cap of $1.60 billion, a PE ratio of -9.98 and a beta of -0.26. Aimmune Therapeutics has a 12 month low of $24.73 and a 12 month high of $42.00.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.86) by ($0.05). On average, equities research analysts expect that Aimmune Therapeutics will post -3.63 EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in AIMT. Tiverton Asset Management LLC purchased a new position in Aimmune Therapeutics in the 2nd quarter worth approximately $145,000. Xact Kapitalforvaltning AB purchased a new position in Aimmune Therapeutics in the 1st quarter worth approximately $207,000. Ardsley Advisory Partners purchased a new position in Aimmune Therapeutics in the 2nd quarter worth approximately $202,000. WINTON GROUP Ltd purchased a new position in Aimmune Therapeutics in the 1st quarter worth approximately $262,000. Finally, Fred Alger Management Inc. purchased a new position in Aimmune Therapeutics in the 2nd quarter worth approximately $269,000. 78.15% of the stock is currently owned by institutional investors.
Several research analysts have recently weighed in on the company. BidaskClub upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 7th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. ValuEngine downgraded Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 7th. Credit Suisse Group set a $40.00 target price on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Monday, August 13th. Finally, Stifel Nicolaus began coverage on Aimmune Therapeutics in a research note on Thursday, September 13th. They issued a “hold” rating and a $33.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. Aimmune Therapeutics presently has an average rating of “Buy” and a consensus price target of $50.90.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.
See Also: What is a stock buyback?
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.